BTK inhibitors were associated with a clinically meaningful incidence of cardiovascular adverse effects (CVAEs), including hypertension, atrial fibrillation, and hemorrhage, according to findings from a meta analysis presented at the
Baseline Cardiovascular Assessment, Monitoring Are Crucial With BTK Inhibitors in CLL and Other Hematologic Malignancies
